Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany
International Journal of Colorectal Disease · 2023
DOI: 10.1007/s00384-023-04397-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2023. Verfasst von Bernd Bokemeyer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Crohn Colitis Centre Minden, North Rhine-Westphalia, Märchenweg 17, 32429, Minden, Germany. bernd.bokemeyer@t-online.de. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galápagos.
Abstract (Originalsprache)
Purpose
Many patients treated for ulcerative colitis (UC) do not achieve clinical remission. This real-world study assessed clinical remission and inadequate response rates among patients with UC in Germany treated with advanced therapies.
Methods
This retrospective chart review included patients with UC newly initiating advanced (index) therapy (anti-TNFα agents, vedolizumab, tofacitinib) from January 2017–September 2019 (index date). Included patients had data for ≥ 12 months before (baseline period) and after the index date (follow-up period). Remission was defined as a partial Mayo score ≤ 1. Indicators of inadequate response were: index therapy discontinuation; therapy adjustments (index therapy dose escalation; augmentation with non-advanced therapies; corticosteroid [CS] use during maintenance therapy); CS dependency (use for ≥ 12 weeks); and UC-related hospitalisation, surgery or emergency department visit. Time to first remission and inadequate response were analyzed using Kaplan–Meier analyses.
Results
Among 149 patients with UC (median age: 40 years), 96 (64.4%) were biologic-naïve and 42 (28.2%) received CS at the index date. Within 12 months, 52 patients (47.2%) were in remission; of these, 13 patients (25.0%) received ≥ 1 therapy adjustment. At 12 months, 55 patients (37.6%) had ≥ 1 indicator of an inadequate response. Median time to remission was longer among biologic-experienced vs biologic-naïve patients (24 vs 7 months; p = 0.012).
Conclusion
Over half of the patients were not in clinical remission after 12 months and more than one-third experienced inadequate response. One-quarter of patients in remission required therapy adjustments. Patients with UC require therapies that are more effective than those currently available to achieve better treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Crohn Colitis Centre Minden, North Rhine-Westphalia, Märchenweg 17, 32429, Minden, Germany. bernd.bokemeyer@t-online.de.
- Real World and Advanced Analytics, Ingress-Health HWM GmbH, Wismar, Mecklenburg-Vorpommern, Germany.
- Medical Affairs, Galapagos Biopharma Deutschland GmbH, Munich, Bavaria, Germany.
- Evidence Generation and Epidemiology, Medical Affairs, Galapagos NV, Mechelen, Antwerp, Belgium.
Förderung
- Galápagos
Zitieren
APA
Bokemeyer, B., Picker, N., Kromer, D., Rosin, L., & Patel, H. (2023). Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-023-04397-7
Vancouver
Bokemeyer B, Picker N, Kromer D, Rosin L, Patel H. Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany. International Journal of Colorectal Disease. 2023. doi:10.1007/s00384-023-04397-7
BibTeX
@article{Bokemeyer2023,
author = {Bokemeyer, Bernd and Picker, Nils and Kromer, Daniel and Rosin, Ludger and Patel, Haridarshan},
title = {Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany},
journal = {International Journal of Colorectal Disease},
year = {2023},
doi = {10.1007/s00384-023-04397-7}
}
EUVIMED